MaxCyte,
Inc.
("MaxCyte" or the "Company")
Total Voting Rights and Block
Listing Return
ROCKVILLE, MD, December 2,
2024: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, announces that pursuant to its block admission
facility, since 31 October 2024 it has issued 256,320 of
common stock, $0.01 par, of the Company ("Common Stock") in
satisfaction of the exercise of share options and/or vesting of
restricted stock units.
Total voting rights
As at 30 November 2024, the total
issued stock capital of the Company following the recent issue of
the new Common Stock is 105,691,189 shares of Common Stock.
Shareholders in the Company may use this figure as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the stock capital of the Company.
Block Listing
Return
MaxCyte also makes the following
notification pursuant to AIM Rule 29 and Schedule Six of the AIM
Rules for Companies, regarding its existing block
listings:
|
Name of applicant:
|
MaxCyte, Inc.
|
|
Name of scheme:
|
MaxCyte Long Term Incentive
Plan
|
|
Period of return:
|
From:
|
2 April 2024
|
To:
|
2 December 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
9,038,342 ordinary shares of common
stock at $0.01
each
|
|
Plus: The amount by which
the block scheme(s) has been increased since the date of the last
return (if any increase has been applied for):
|
Nil
|
|
Less: Number
of securities issued/allotted under
scheme(s) during period (see LR3.5.7G):
|
1,416,648 ordinary shares of common
stock at $0.01
each
|
|
Equals: Balance under
scheme(s) not yet issued/allotted at end of period:
|
7,621,694 ordinary shares of common
stock at $0.01
each
|
|
|
|
|
|
|
|
Name of contact:
|
Douglas Swirsky, Chief Financial
Officer
|
|
Telephone number of
contact:
|
+1 301 944 1700
|
For further information, please
contact:
|
|
MaxCyte Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR
Adviser
ICR
Healthcare
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
|
|
|
|
|
|
|
|
|
|
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology platform, as well as
scientific, technical, and regulatory support, we aim to guide them
on their journey to transform human health. Learn more
at maxcyte.com and follow us on X and LinkedIn.